BiotechTube

Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus + Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus + Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus + Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tetanus

Conditions

Tetanus, Diphtheria, Pertussis, Measles, Polio

Trial Timeline

Apr 1, 2011 → Sep 1, 2013

NCT ID
NCT01346293

About Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus + Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus + Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus + Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus

Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus + Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus + Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus + Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus is a phase 3 stage product being developed by Sanofi for Tetanus. The current trial status is completed. This product is registered under clinical trial identifier NCT01346293. Target conditions include Tetanus, Diphtheria, Pertussis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01346293Phase 3Completed

Competing Products

10 competing products in Tetanus

See all competitors
ProductCompanyStageHype Score
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) + Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)SanofiApproved
84
Tetanus-diphtheria-acellular pertussis (Tdap) vaccineSanofiApproved
84
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed + Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis AdsorbedSanofiApproved
84
DTaP-IPV/Hib Combined vaccine + DTaP-IPV vaccine and Hib vaccine + DTaP-IPV/Hib Combined vaccineSanofiPhase 3
76
Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed + Diphtheria and Tetanus toxoids adsorbedSanofiPhase 3
76
Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine + Tetanus and Diphtheria Toxoids Adsorbed For Adult UseSanofiApproved
84
Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) + DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)SanofiPhase 3
76
Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1 + Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2 + Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3 + Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4 + Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed + Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis VaccineSanofiPhase 1/2
40
Investigational Tdap vaccine Formulation B + Investigational Tdap vaccine Formulation C + Investigational Tdap vaccine Formulation A + Investigational Tdap vaccine Formulation D + Licensed Tdap vaccineSanofiPhase 1
32
Tetanus Immune Globulin (Human) + Diphtheria-Tetanus Toxoids AdsorbedGrifolsApproved
82

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84